Drug intelligence / Profile preview

68Ga-PSMA-CYC

Development stage: Unknown
Lead developer: The First Hospital of Fujian Medical University
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-PSMA-CYC is a novel gallium-68 labeled radiopharmaceutical designed for positron emission tomography (PET) imaging of prostate cancer. It specifically targets the prostate-specific membrane antigen (PSMA), which is highly overexpressed on the surface of prostate cancer cells. Developed by the First Affiliated Hospital of Fujian Medical University, this tracer is being evaluated for its safety, biodistribution, and diagnostic performance in the staging and restaging of prostate cancer, often in head-to-head comparisons with established tracers like 68Ga-PSMA-617 and 68Ga-PSMA-11.

Other names: 68Ga-labeled PSMA-CYC

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 68Ga-PSMA-CYC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-PSMA-CYC.

Explore the full profile